Apollo Ventures
Overview
Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself . They leverage a combination of traditional funding and venture building to create value in Europe and the US, partnering with scientific experts and top institutions . Their approach aims to enable breakthroughs in biotechnology to enhance healthy lifespans and reduce healthcare costs .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Auron Therapeutics | Feb 2025 | Series B | - |
| Therini Bio | May 2025 | Series A Extension | - |
| Aeovian Pharmaceuticals | Dec 2017 | Seed | Lead |
Key People
Alexandra Sharon Bause
Co-Founder, Investment Director Head Of VentureLabs
Christopher R. Shepard
Venture Partner
Cyrus Arman
Venture Partner
Laurent Audoly
Executive Partner
Marianne Mertens
Partner
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Apollo Ventures based?
Apollo Ventures is headquartered in Berlin, Berlin, Germany.
When was Apollo Ventures founded?
Apollo Ventures was founded in 2016.
How many portfolio companies does Apollo Ventures have?
Apollo Ventures has 3 portfolio companies in Caplight's dataset.
What are some companies in Apollo Ventures's portfolio?
Portfolio companies visible on Caplight include Auron Therapeutics, Therini Bio, Aeovian Pharmaceuticals.
What was Apollo Ventures's most recent investment shown here?
Apollo Ventures's most recent investment in this portfolio sample was in Therini Bio in 2025.
What sectors does Apollo Ventures focus on?
Apollo Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does Apollo Ventures focus on?
Apollo Ventures typically invests at the Early stage.
What is Apollo Ventures's AUM?
Apollo Ventures's assets under management are estimated between $100.0M and $250.0M.